An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Viberzi

Chemical Nameeluxadoline
Dosage FormTablet (oral; 75 mg, 100 mg)
Drug ClassReceptor antagonists
SystemDigestive
CompanyAllergan
Approval Year2015

Indication

  • To treat irritable bowel syndrome with diarrhea (IBS-D) in adult men and women.
Last updated on 3/10/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Viberzi (eluxadoline) Prescribing Information2018Allergan USA, Inc., Madison, NJ
Document TitleYearSource
Eluxadoline for treating irritable bowel syndrome with diarrhoea.2017NICE
Document TitleYearSource
Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis.2020Gut
Document TitleYearSource
Canadian Association of Gastroenterology Clinical Practice guideline for the management of irritable bowel syndrome (IBS). 2020Journal of the Canadian Association of Gastroenterology